Appendix B. Sources of evidence considered by the Committee

Appendix B. Sources of evidence considered by the Committee

The following documentation and opinions were made available to the Committee:

A. The Assessment Report for this appraisal was prepared by Southampton Health Technology Assessment Centre.

Green C, Colquitt JL, Kirby J et al. Clinical and cost-effectiveness of once daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation, November 2003.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, Assessment Report and the Appraisal Consultation Document (ACD). Consultee organisations are provided with the opportunity to appeal against the Final Appraisal Determination.

I) Manufacturer/sponsors:

  • Dermal Laboratories

  • GlaxoSmithKline

  • Novartis

  • Pliva Pharma

  • Schering-Plough

  • Stiefel Laboratories (UK)

  • Typharm

  • Waymade Healthcare

  • Yamanouchi

II) Professional/specialist, patient/carer and other groups:

  • British Association of Dermatologists

  • British Generic Manufacturers' Association

  • Department of Health

  • Hounslow Primary Care Trust

  • National Eczema Society

  • Primary Care Dermatology Society

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Physicians

  • Royal Pharmaceutical Society of Great Britain

  • Skin Care Campaign

  • Welsh Assembly Government

III) Commentator organisations (without the right of appeal):

  • NHS Confederation

  • NHS Purchasing and Supply Agency

  • NHS Quality Improvement Scotland

  • Skin Treatment and Research Trust

C. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on the frequency of application of topical corticosteroids for atopic eczema by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Ms Sandra Lawton, Nurse Consultant Dermatology, Queen's Medical Centre, Nottingham

  • Dr Celia Moss, Consultant Dermatologist, Birmingham Children's Hospital

  • Ms Sue Ward, Information and Education Manager, National Eczema Society